Ticker

Cognition Therapeutics (NASDAQ: CGTX) executives told investors at the Needham conference that the company is preparing to advance its once-daily oral candidate zervimesine into late-stage development, with an initial focus on psychosis symptoms in dementia with Lewy bodies (DLB) while continuing to run a large National Institute on Aging (NIA)-funded Alzheimer's disease study. Pipeline focus shifts

PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi intends to present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13th at 3:00 p.m. Eastern Time. During her presentation, Ms. Ricciardi will provide…

Advancing Zervimesine (CT1812) towards late-stage trials for  dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.  (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders, has published CEO Lisa Ricciardi's…

Cognition Therapeutics (NASDAQ: CGTX) used its fourth-quarter and full-year 2025 earnings call to outline a shift in development priorities for its lead candidate, zervimesine (CT-1812), with management saying it will now focus on pursuing a registration path in dementia with Lewy bodies (DLB) psychosis. Company prioritizes DLB psychosis after Phase II data and regulator feedback Chief

Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript